AscellaHealth Releases Q2 2024 Specialty & Rare Pipeline Digest™: Increased Approvals Signal Growing Demand and Utilization of Specialty Pharmaceuticals
17 Julio 2024 - 9:00AM
Business Wire
AscellaHealth, a global partner that delivers proven end-to-end
solutions to both life sciences and healthcare companies to enhance
the quality of life for patients with complex, chronic conditions,
today released its latest Specialty & Rare Pipeline Digest™,
the industry’s most comprehensive quarterly resource of new,
pending and upcoming specialty and rare disease drug launches, cell
and gene therapies (CGT), biosimilars and generics. This
complimentary digital publication provides timely product updates
to support the specialty drug market needs of stakeholders and
decision-makers.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240717294481/en/
(Graphic: Business Wire)
“The Q2 2024 Digest indicates a notable increase in specialty
drug approvals and the introduction of additional cell and gene
therapies compared to the previous quarter,” says Andy Szczotka,
PharmD, chief pharmacy officer, AscellaHealth. “This upward trend
underscores the growing demand for specialty medications and
highlights the essential role of AscellaHealth in addressing the
needs of millions of individuals worldwide who are affected by
complex, chronic conditions or rare diseases.”
This vast compilation of industry pipeline information
exemplifies our commitment to being at the forefront of
disseminating and sharing knowledge, providing valuable insights
and data to support our partners, clients and the entire specialty
pharmaceutical ecosystem.
“Recognized as an important resource for the industry, The
Specialty & Rare Pipeline Digest™ captures key data
demonstrating the rapid growth of the specialty pharmaceutical
market,” states Dea Belazi, CEO, AscellaHealth. “As the number of
approved drugs rises, so does the need for specialized care and
innovative solutions to ensure patient access and adherence to
treatment. These trends largely account for the growth of
AscellaHealth as a single-source industry partner, providing
end-to-end, global solutions which result in the streamlined
commercialization of specialty drugs, cost savings for clients and
an optimal treatment journey for patients and caregivers.”
AscellaHealth streamlines the pathway to successful drug
commercialization and enhanced access by offering innovative
solutions across the entire product lifecycle and care continuum.
With a comprehensive suite of services, AscellaHealth guides life
sciences clients through every stage of the commercialization
process, from clinical trials and approval to transitioning
patients onto approved therapies.
Access the latest Specialty & Rare Pipeline Digest™
here.
About AscellaHealth LLC AscellaHealth is a global partner
that delivers proven end-to-end solutions to both life sciences and
healthcare companies to enhance quality of life for patients with
complex, chronic conditions. A dedicated team gets critical
healthcare products from manufacturers to patients while ensuring
an efficient flow of funds between payers and pharma. Visit
www.AscellaHealth.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240717294481/en/
Media: Nicole Dufour CPR Communications
ndufour@cpronline.com 201.641.1911 x 54